SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TLSI

TriSalus Life Sciences, Inc. (TLSI)

NASDAQ: TLSI · USD
Healthcare · Medical Devices
$2.32+$0.14 (+6.67%)
 
Market cap
$143M
Insider Score
Analyst consensus
Market Cap$143.14M-53.2%
Revenue (ttm)$46.39M
Net Income-$26.25M
EPS-$0.41
Shares Out61.70M
PE Ration/a
Forward PE-9.28
Dividendn/a
Ex-Dividend Daten/a
Volume539,262
Open$2.19
Previous Close$2.17
Day's Range$2.19 - $2.37
52-Week Range$2.17 - $7.95
Beta0.51
AnalystsStrong Buy
Price Target$7.80(+236.21%)
Earnings DateNov 10, 2026

About TLSI

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Address
6272 West 91st Avenue, Westminster, CO, 80031, United States
Market Cap
143 million
Employees
102
Industrial Classification
Medical Devices

TriSalus Life Sciences, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
46th Percentile Overall Score
TLSI InsiderScore:65 / 99

TriSalus Life Sciences, Inc. scored higher than 46% of companies evaluated by InsiderBuying, and ranked 34th out of 57 stocks in the healthcare sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at TriSalus Life Sciences, Inc. bought $294.2K of stock across 4 purchases in the last 90 days, the largest of them $112.0K.

Stake Increase

The average purchase added about 13% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$6.89K
Bought
$2.12M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $7.50 (+223.3%)

2 firms rating TLSI in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
+6.67%
5 Days
-4.53%
1 Month
-36.61%
6 Months
-28.83%
1 Year
-53.23%

$TLSI stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in TLSI holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TLSI's directors and management

Net Shares Purchased by Insiders−800k−400k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TLSI Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New TLSI patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TLSI from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from TLSI’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
65.57
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
35

News check: Q3 revenue miss and guidance reset dominated coverage, offsetting modest 11.3% revenue growth; analyst fair value assessments turned negative.

Recent Insider Activity

Buys
10
Sells
5
Buy Value
$2.12M
Distinct Buyers
5

Insider Score Trend Over Time

+13.2 since Nov 16
0255075100Nov 16 — Insider Score 52.4Nov 17 — Insider Score 50.7Nov 18 — Insider Score 49.0Nov 19 — Insider Score 47.7Nov 20 — Insider Score 65.9Nov 21 — Insider Score 65.5Nov 22 — Insider Score 65.6Nov 16Nov 19Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

QQQSInvesco NASDAQ Future Gen 200 ETF0.26%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.19%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.14%
FLQSFranklin U.S. Small Cap Multifactor Index ETF0.01%

Weight is the stock’s share of each fund’s holdings.